Products for Research Use Only

Sulfasalazine-d4

CAT: 0804-HY-14655SSize: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-14655SSize:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sulfasalazine-d4 is the deuterium labeled Sulfasalazine. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer[1][2][3][4].
CAS Number
1346606-50-5
UNSPSC
12352005
Target
Antibiotic; Apoptosis; Autophagy; Bacterial; Ferroptosis; Isotope-Labeled Compounds; NF-κB
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Apoptosis; Autophagy; NF-κB; Others
Field of Research
Cancer; Infection; Inflammation/Immunology
Purity
99.28
Solubility
DMF : ≥ 30mg/mL|DMSO : 100 mg/mL (ultrasonic)
Smiles
[2H]C1=NC(NS(=O)(C2=CC=C(C=C2)/N=N/C3=CC(C(O)=O)=C(C=C3)O)=O)=C([2H])C([2H])=C1[2H]
Molecular Formula
C18H10D4N4O5S
Molecular Weight
402.42
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Mao C, et al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. 2021;593 (7860) :586-590.|[3]Wahl C, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest. 1998 Mar 1;101 (5) :1163-74.|[4]Sykes L, et al. Sulfasalazine augments a pro-inflammatory response in interleukin-1β-stimulated amniocytes and myocytes. Immunology. 2015 Dec;146 (4) :630-44.|[5]Chung WJ, et al. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J Neurochem. 2009 Jul;110 (1) :182-93.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported